AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04392674 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: the new tissue containment system
Description: using the new tissue containment system during Laparoscopic myomectomy morcellation
Study NCT00647244 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir disoproxil fumarate
Description: Tenofovir disoproxil 245 mg oral tablet once daily
Study NCT00647244 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abacavir
Description: Abacavir 300 mg oral tablet twice daily
Study NCT02072252 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Phone Application
Description: Mobile phone app teaching cognitive behavioral skills
Study NCT02947802 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Effectiveness of Labels in Reducing Purchasing of Sugar Sweetened Beverages
Description: In one of our parallel assigned conditions participants will receive additional information (e.g., an intervention) of effectiveness information. These consumers will learn how effective these labels were in reducing the purchasing of sugar sweetened beverages in a recent study.
Study NCT02947802 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control condition
Description: In one of our parallel assigned conditions participants will receive no additional information and be asked to rate their support for the label.
Study NCT03088644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54175446
Description: JNJ-54175446 up to 600 mg suspension for oral dose administration.
Study NCT03088644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-JNJ-64413739
Description: 18F-JNJ-64413739 fluid for injection administered intravenously.
Study NCT00804648 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Timolol hemihydrate
Description: 0.5%
Study NCT03026816 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Epidural Spinal Cord Stimulation
Description: epidural spinal cord stimulator
Study NCT01510990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Description: gefitinib 250mg/day daily
Study NCT03863561 — intervention group
Intervention type: BEHAVIORAL
Intervention: Diabetes self-management education (DSME) program
Description: Diabetes educators customized care paths for their patients based on their individual responses to the SCPI questions. Patients met with an educator five to seven times over the course of three to four months.
Study NCT01637532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab and interferon alpha 2-b
Description: During first three chemotherapy cycles, tocilizumab and/or Peg-Intron are added.~Tocilizumab is given in a dose-escalation scheme (1,2,4,8mg/kg n=3) and Peg-Intron is adminstered subcutaneously 1.0ug/kg
Study NCT01637532 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Carboplatin and Caelyx or doxorubicin
Description: Standard chemotherapeutic care given in every arm as standard care. A total of 6 cycles is the aim.
Study NCT01637532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin and Caelyx or doxorubicin
Description: Standard chemotherapeutic care given in every arm as standard care. A total of 6 cycles is the aim.
Study NCT03122145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capsaicin
Description: Participants will inspire deeply through the nebulizer coupled to the facemask and pneumotachograph. Each test inhalation will be separated by an interval of 2 minutes. This experimental trial consists of six (instead of 8) test solutions: 0, 25, 50, 100, 200 and 500 μM capsaicin in 80% physiological saline, 20% ethanol. Participants will inhale single vital capacity breaths of capsaicin solution via an air-powered dosimeter (KoKoDigidoser; Pulmonary Data Services Instrumentation Inc; Louisville, CO). The reflex cough test ends when the participant coughs at least 2 times in response to one inhalation dose, or receives a dose of the highest concentration (500 μM).
Study NCT03122145 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Videofluoroscopic swallow study
Description: The swallowing systems core laboratory is fully equipped to perform videofluoroscopy with a c-arm (OEC 9900) that is dedicated solely to research purposes. Videofluoroscopy recordings will be kept to a minimum and turned on only during completion of a specific testing task. Video recording and images captured during the videofluoroscopy will be synced and saved for data analysis. Videofluoroscopy allows for time-synced, frame-by-frame data analysis for the specific measures taken during swallowing tasks. The physiological swallowing measures (temporal and kinematic of the base of tongue, oropharynx, and hyolarynx complex during swallowing) to be analyzed cannot be visualized with any other technique. All swallowing tasks will be completed using barium in order to visualize the bolus during movement of various swallowing muscles and structures.
Study NCT00804648 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Timolol maleate gel forming solution
Description: 0.5%
Study NCT02070328 — intervention group
Intervention type: OTHER
Intervention: Registry
Study NCT03794427 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: unilateral lumbosacral nerve block
Description: Patients will receive unilateral lumbosacral nerve block (sciatic nerve block and paravertebral block at levels L3-L4 and L4-L5). The sciatic nerve will be injected by 20 ml of the anesthetic mixture whereas levels L3-L4 and L4-L5 will be injected by a total of 20 ml of the anesthetic mixture without exceeding the maximum injected volume of 1 ml/kg.
Study NCT03794427 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Spinal anesthesia
Description: Patients will receive spinal anesthesia (3 ml of 0.5% bupivacaine)
Study NCT03794427 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo at the spinal anesthesia level
Description: Patients will receive 1 ml normal saline at the spinal anesthesia level (L3-L4 or L4-L5).
Study NCT03794427 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo at lumbosacral level
Description: Patients will receive normal saline at the sciatic, L3-L4 and L4-L5 levels
Study NCT04185077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Description: Bivalirudin (Salubris Pharmaceuticals Co) was given as a bolus of 0.75mg/kg followed by infusion of 1.75mg/kg/h during the PCI procedure and for at least 30 minutes but no more than 4 hours afterwards. Following this mandatory infusion, a reduced-dose infusion (0.2mg/kg/h) for up to 20 hours could be administered at physician discretion. An additional bivalirudin bolus of0.3mg/kgwasgivenif the activatedclotting time 5minutes after the initial bolus (measuredwith the Hemotec assay) was less than 225 seconds.
Study NCT04185077 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin
Description: a bolus dose of 100 U/kg was administered according to current guidelines.Additional heparinwasadministered if the post-bolus activated clotting time was less than 225 seconds.
Study NCT02783547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SyB C-1101 and Azacytidine
Description: This study is a multi-center open-label study to assess the tolerability of oral administration of SyB C-1101 twice daily from Day 1 to Day 21 in combination with subcutaneous administration or intravenous drip infusion of azacitidine once daily at a dose of 75 mg/m2 (body surface) for 7 days during the period between Day 8 and Day 16, and to estimate the recommended dose (RD) of C-1101.~SyB C-1101 will be administered at a daily dose of 560 mg or 840 mg in each of the 2 cohorts for a treatment period of 1 cycle for 28 days, including 21 days for SyB C-1101 treatment followed by 7 days of follow-up.
Study NCT03238274 — intervention group
Intervention type: DEVICE
Intervention: Sofia 2 Lyme FIA testing
Description: IVD testing of whole blood or serum/plasma to aid in the detection of anti-B. burgdorferi IgG / IgM antibody
Study NCT00939887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04455242
Description: Single dose of up to 30 mg PF-04455242, delivered in capsule.
Study NCT03815448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Participants randomized to methotrexate group will receive active drug, methotrexate. Starting from 5 mg/week, the dosage will be adjusted to 10 mg/week if the participants can tolerate for 2 weeks. After 2 weeks, the dosage will be adjusted to 15 mg/week until the end of the study if the participants can tolerate.
Study NCT03815448 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants randomized to placebo group will receive placebo tablets. Starting from 5 mg/week for 2 weeks, the dosage will be adjusted to 10 mg/week; after 2 weeks, the dosage will be adjusted to 15 mg/week until the end of the study.
Study NCT03447496 — intervention group
Intervention type: PROCEDURE
Intervention: Closed reduction
Description: The children were treated with closed reduction.
Study NCT03447496 — intervention group
Intervention type: PROCEDURE
Intervention: Open reduction
Description: The children were treated with Open reduction.
Study NCT01807481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mircera
Description: Once Monthly Mircera
Study NCT04512482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bromelain
Description: The subjects were randomized to either receive the bromelain pre-rinse or the powdered sugar placebo pre-rinse. Subjects then had a 5-9 day washout period and was then exposed to the other intervention.
Study NCT04512482 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bromelain
Description: The subjects were randomized to either receive the bromelain pre-rinse or the powdered sugar placebo pre-rinse. Subjects then had a 5-9 day washout period and was then exposed to the other intervention.
Study NCT04512482 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Powdered sugar
Description: The subjects were randomized to either receive the bromelain pre-rinse or the powdered sugar placebo pre-rinse. Subjects then had a 5-9 day washout period and was then exposed to the other intervention.
Study NCT04512482 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Powdered sugar
Description: The subjects were randomized to either receive the bromelain pre-rinse or the powdered sugar placebo pre-rinse. Subjects then had a 5-9 day washout period and was then exposed to the other intervention.
Study NCT01066767 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fexofenadine
Description: Fexofenadine Hydrochloride 180 mg Tablets
Study NCT01066767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fexofenadine
Description: Fexofenadine Hydrochloride 180 mg Tablets
Study NCT02509364 — intervention group
Intervention type: OTHER
Intervention: No intervention
Study NCT00322049 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tetravalent live attenuated dengue vaccine
Description: DEN candidate vaccine: One dose of the tetravalent, live attenuated DEN vaccine candidate, F17, contains dengue serotype 1, 2, 3 and 4 vaccines. This formulation contains 50 mcg/mL neomycin base, 5.5% lactose, and 1.9 g/dL human serum albumin; for subcutaneous injection.~Infants received dengue vaccine at study months 0 and 6 or control vaccine (varicella vaccine at study month 0 and Haemophilus influenzae Type b Conjugate vaccine at study month 6). Both control vaccines are licensed for use in Thailand.~All infants subsequently received an inactivated JE vaccine approximately one and 1.5 months following dengue vaccine dose 2. The licensed JE vaccine in liquid form, was dosed at 0.25 ml for subcutaneous injection.~A booster dose of DEN vaccine was given to all subjects previously vaccinated with DEN vaccine in Dengue -001. The booster dose was administered approximately 42 months after dose 2 (at the Year 3 visit).
Study NCT00322049 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Varicella vaccine and Haemophilus influenzae Type b Conjugate vaccine
Description: Infants received dengue vaccine at study months 0 and 6 or control vaccine (varicella vaccine at study month 0 and Haemophilus influenzae Type b Conjugate vaccine at study month 6). Both control vaccines are licensed for use in Thailand.
Study NCT00773851 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: mesh fixation by transfacial sutures
Description: mesh fixation by transfacial sutures
Study NCT00773851 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: mesh fixation by staples
Description: mesh fixation by staples
Study NCT03609489 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine, 1000mg/m2, oral administration, twice daily (once in the morning and once in the evening with an interval of 12 hours, equivalent to a total daily dose of 2000 mg/m2), continuous medication for 14 days and off for 7 days. Every 21 days is a cycle, and there shall be a total of 8 cycles. If the subject is still unable to tolerate toxicity after experiencing two dose adjustments, he/she should be moved out of the group.
Study NCT00960791 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AZD1656
Description: Oral single dose
Study NCT01152125 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow stem cells
Description: Stem cells isolated from the patient's own bone marrow.
Study NCT03609489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine, 1000mg/m2, oral administration, twice daily (once in the morning and once in the evening with an interval of 12 hours, equivalent to a total daily dose of 2000 mg/m2), continuous medication for 14 days and off for 7 days. Every 21 days is a cycle, and there shall be a total of 8 cycles. If the subject is still unable to tolerate toxicity after experiencing two dose adjustments, he/she should be moved out of the group.
Study NCT03609489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib, 500 mg, administered orally (after breakfast) once daily from day 1 to day 21 (including day 21) with continuous administration. Every 21 days serve as a cycle. If after 2 dose adjustments, the subject is still unable to tolerate toxicity, he/she should be moved out of the group.
Study NCT03354572 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetyl cysteine
Description: acetyl cysteine 150 mg/kg prior to surgery
Study NCT03354572 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: saline 0.9% prior to surgery
Study NCT01719679 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: School Located Vaccine (SLV) Program
Description: A community vaccinator will administer vaccines to students whose parents consent for their child to participate
Study NCT01332097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCT197
Study NCT01332097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone placebo
Description: capsules
Study NCT01332097 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone placebo
Description: capsules
Study NCT01332097 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BCT197 placebo
Description: capsules
Study NCT01332097 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BCT197 placebo
Description: capsules
Study NCT01332097 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: capsules
Study NCT00710567 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: DuraHeart Left Ventricular Assist System (LVAS)
Description: The DuraHeart LVAS is implanted in using open heart surgery
Study NCT03117309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab 240 mg
Description: PART A Nivolumab 240 mg IV every 2 weeks x 6 then initial disease assessment
Study NCT03117309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab 1mg/kg
Description: Ipilimumab 1 mg/kg every 3 weeks x 4
Study NCT03117309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab 3mg/kg
Description: In combination with Ipilimumab
Study NCT03117309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab 360mg
Description: Continue Nivolumab 360 mg IV every 3 weeks
Study NCT01068717 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Saxagliptin, 2.5 mg + Metformin, 500 mg (fasted state)
Description: Tablets, oral, 2.5-mg saxagliptin and 500-mg metformin, once daily, 1 week
Study NCT01068717 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Saxagliptin, 2.5 mg /Metformin, 500 mg FDC (fasted state)
Description: Tablets, oral, 2.5-mg saxagliptin/500-mg metformin fixed-dose combination (FDC), once daily, 1 week
Study NCT01068717 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Saxagliptin, 2.5 mg + Metformin, 500 mg (fed state)
Description: Tablets, oral, 2.5-mg saxagliptin and 500-mg metformin, once daily, 1 week
Study NCT01068717 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Saxagliptin, 2.5 mg /Metformin, 500 mg FDC (fed state)
Description: Tablets, oral, 2.5-mg saxagliptin and 500-mg metformin FDC, once daily, 1 week
Study NCT03810521 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: umbilical cord derived-mesenchymal stromal cells
Description: Intra-articular infiltration of umbilical cord derived-mesenchymal stromal cells
Study NCT01359852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [11C] JNJ-42491293
Description: Part B:\[11C\] JNJ-42491293 (300 to 370 MBq) will be dosed as an i.v. bolus injection, have a 90 minute PET scan and have arterial and venous blood sampling.
Study NCT01359852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [11C] JNJ-42491293 + JNJ-40411813
Description: Part C:\[11C\] JNJ-42491293 (300 to 370 MBq) will be dosed as an i.v.bolus injection. Volunteers will be pre-treated with JNJ-40411813 between 1.5 to 3 hours prior to the second and prior to the third PET scan
Study NCT01359852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [11C] JNJ-42491293 + JNJ-40411813
Description: Part D:\[11C\] JNJ-42491293 (300 to 370 MBq) will be dosed as an i.v. bolus injection.~Volunteers will be treated with a single dose of up to 500 mg JNJ-40411813 prior to the second scan and will have a third scan at least 2 hours later to evaluate the rate of clearance of JNJ-40411813 from the brain
Study NCT01359852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [11C] JNJ-42491293
Description: Part A: \[11C\] JNJ-42491293 (300 to 370 MBq) will be dosed as an i.v. bolus injection and have a 120 minute PET scan.
Study NCT02840435 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sit to Quit
Description: Sit to Quit(STQ) is a smoking cessation program adapted from Mindfulness Training for Smokers (MTS) with core content available on the STQ video. STQ contains many elements found in traditional interventions (e.g. instruction on planning and structuring a quit day, garnering support from others, assessment of prior relapse occasions, development of strategies to avoid triggers). In addition, STQ provides instruction in various mindfulness practices and in how to apply mindfulness skills to manage common causes of relapse. Exercises are provided, and it is recommended to learn the skill experientially. STQ requests that participants practice guided meditation each day using an audio recording and employ other mindfulness practices targeted to manage relapse challenges. Participants will also receive the STQ Participant Manual, which provides all the instruction found in the STQ Video, but provides additional discussion of topics for smokers who desire additional material.
Study NCT02551536 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Montelukast
Study NCT02551536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast
Study NCT02551536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fexofenadine
Description: group B received FDC tablet of montelukast 10mg and fexofenadine 120 mg O.D
Study NCT02551536 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levocetrizine
Description: group A recieved FDC tablet of montelukast 10 mg and levocetrizine 5mg O.D
Study NCT00006017 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: becatecarin
Description: Arm I: Patients receive rebeccamycin analogue IV over 1 hour on day 1. Arm II: Patients receive rebeccamycin analogue IV over 1 hour on days 1-5. Treatment for both arms repeats every 3 weeks for 6-8 courses in the absence of disease progression or unacceptable toxicity.
Study NCT04613700 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Secretin
Description: Native hormone
Study NCT04613700 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline
Study NCT00861770 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Ultrafiltration
Description: Ultrafiltration based on standard of care.
Study NCT00861770 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrafiltration using BVM
Description: Ultrafiltration will be guided by blood volume measurement results.
Study NCT02840435 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Quit for Life
Description: Quit for Life integrates telephone counseling, written materials, NRT, and an online program called Web Coach. Web Coach is an interactive internet-based support system that provides health information on smoking cessation, assistance in the development of quit strategies, and an interactive blog to interact with other smokers. Web Coach is used by approximately 70% of AWI callers. Web Coach is not a complete program, but instead is designed to supplement AWI phone-based therapy. In addition, Quit for Life also provides the Quit Guide, which is a smoking cessation manual with written instructions on the use of medications, planning a quit day, and cessation-related cognitive skills.